Mapping of transcription termination within the S segment of SFTS phlebovirus facilitated the generation of NSs-deletant viruses by Brennan, Benjamin et al.
Mapping of Transcription Termination
within the S Segment of SFTS
Phlebovirus Facilitated Generation of
NSs Deletant Viruses
Benjamin Brennan, Veronica V. Rezelj,* Richard M. Elliott†
MRC—University of Glasgow Centre for Virus Research, Glasgow, Scotland, United Kingdom
ABSTRACT SFTS phlebovirus (SFTSV) is an emerging tick-borne bunyavirus that
was ﬁrst reported in China in 2009. Here we report the generation of a recombi-
nant SFTSV (rHB29NSsKO) that cannot express the viral nonstructural protein
(NSs) upon infection of cells in culture. We show that rHB29NSsKO replication ki-
netics are greater in interferon (IFN)-incompetent cells and that the virus is unable
to suppress IFN induced in response to viral replication. The data conﬁrm for the
ﬁrst time in the context of virus infection that NSs acts as a virally encoded IFN an-
tagonist and that NSs is dispensable for virus replication. Using 3= rapid ampliﬁca-
tion of cDNA ends (RACE), we mapped the 3= end of the N and NSs mRNAs, show-
ing that the mRNAs terminate within the coding region of the opposite open
reading frame. We show that the 3= end of the N mRNA terminates upstream of a
5=-GCCAGCC-3= motif present in the viral genomic RNA. With this knowledge, and us-
ing virus-like particles, we could demonstrate that the last 36 nucleotides of the NSs
open reading frame (ORF) were needed to ensure the efﬁcient termination of the N
mRNA and were required for recombinant virus rescue. We demonstrate that it is
possible to recover viruses lacking NSs (expressing just a 12-amino-acid NSs peptide
or encoding enhanced green ﬂuorescent protein [eGFP]) or an NSs-eGFP fusion
protein in the NSs locus. This opens the possibility for further studies of NSs and
potentially the design of attenuated viruses for vaccination studies.
IMPORTANCE SFTS phlebovirus (SFTSV) and related tick-borne viruses have emerged
globally since 2009. SFTSV has been shown to cause severe disease in humans. For
bunyaviruses, it has been well documented that the nonstructural protein (NSs) en-
ables the virus to counteract the human innate antiviral defenses and that NSs is
one of the major determinants of virulence in infection. Therefore, the use of re-
verse genetics systems to engineer viruses lacking NSs is an attractive strategy
to rationally attenuate bunyaviruses. Here we report the generation of several re-
combinant SFTS viruses that cannot express the NSs protein or have the NSs
open reading frame replaced with a reporter gene. These viruses cannot antago-
nize the mammalian interferon (IFN) response mounted to virus infection. The
generation of NSs-lacking viruses was achieved by mapping the transcriptional
termination of two S-segment-derived subgenomic mRNAs, which revealed that
transcription termination occurs upstream of a 5=-GCCAGCC-3= motif present in
the virus genomic S RNA.
KEYWORDS nonstructural protein, phlebovirus, reporter virus, SFTSV, emerging
pathogen, transcriptional regulation
The recently reclassiﬁed Bunyavirales is an order containing over 350 named virusisolates that are classiﬁed into 9 families of viruses, containing 13 genera. In the
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genus is now classiﬁed within the Phenuiviridae family (https://talk.ictvonline.org/
taxonomy). All phleboviruses share a genome structure that comprises three segments
of negative-sense or ambisense RNA (1, 2). The viral genome is composed of the small
(S), medium (M), and large (L) RNA segments. The S segment encodes the nucleocapsid
(N) protein, the M segment encodes the precursor for the viral glycoproteins (Gn and
Gc), and the L segment encodes the viral RNA-dependent RNA polymerase (RdRp).
Some viruses within the genus also encode nonstructural proteins within their S or M
segments (3).
The phleboviral S segment utilizes an ambisense coding strategy to express the N
and nonstructural (NSs) proteins separated by an untranslated intergenic region (IGR).
The N protein is translated from a subgenomic mRNA transcribed from the genomic
RNA, while the NSs protein is translated from a subgenomic mRNA transcribed from
the antigenomic RNA (4, 5). Viral mRNA transcripts contain a 5= cap structure that
is obtained from host cell mRNAs through a cap-snatching mechanism, facilitated
through the utilization of an endonuclease domain present within the N-terminal
region of the RdRp (6, 7). Previous work conﬁrmed that unlike cellular mRNAs,
phlebovirus-derived mRNAs are not polyadenylated at their 3= ends (8) and are much
smaller in size than the genomic or antigenomic RNA from which they are transcribed
(9–11). Work by numerous groups has mapped the 3= end of the N and NSs mRNAs for
several viruses within the Phlebovirus genus, such as Rift Valley fever phlebovirus (RVFV)
(11–13), sandﬂy fever Sicilian virus (SFSV) (12), Toscana virus (TOSV) (12, 14), Punta Toro
phlebovirus (PTV) (8), and Uukuniemi phlebovirus (UUKV) (6). These data demonstrated
that the mRNAs derived from the S segment overlapped with each other and that the
3= ends of the mRNAs mapped to regions within or just ﬂanking the IGR. It was found
for RVFV that transcription termination of both the N and NSs mRNA occurred 3 to 4
nucleotides (nt) upstream of a 5=-(G/A)CUGC1–3-3= motif present in the IGR of the RVFV
S segment (11, 12). Lara et al. reﬁned this termination signal sequence motif to be
5=-GCUGC-3=. The latter work also further demonstrated that some sequence variation
is tolerated to maintain the termination function of the motif, with 5=-GCAGC-3=
identiﬁed as being the sequence responsible for the transcriptional termination of the
RVFV L segment (13).
Severe fever with thrombocytopenia syndrome virus (SFTSV), or SFTS phlebovirus, is
a novel tick-borne phlebovirus that emerged in China in 2009 (15). The virus caused
severe disease in humans, with patients presenting with thrombocytopenia, hemor-
rhagic manifestations, and multiorgan failure (15, 16), with a case fatality rate ranging
from 12 to 15%. Both infectious virus and viral RNA have been isolated from Haema-
physalis longicornis ticks, while viral RNA only has been isolated from Riphicephalus
microplus ticks collected in China (15, 17). Retrospective testing and active surveillance
of patients presenting with SFTS-like symptoms led to the identiﬁcation of the virus in
Japan (18) and South Korea (19–21). Other tick-borne phleboviruses have also been
recently discovered and assigned within the Phlebovirus genus, with a broad global
distribution and a range of pathogenicity associated with infection of humans (3). Work
rapidly focused on establishing the mechanisms by which SFTSV could cause such
severe disease. SFTSV NSs was characterized as a potent antagonist of the mammalian
interferon (IFN) response (targeting both induction and signaling pathways) (22–27).
Various studies have indicated that as seen with other bunyaviruses, SFTSV NSs is a
potent IFN antagonist and could potentially be a major determinant of virulence
(28–32).
Reverse genetics systems for the recovery of recombinant phleboviruses such as
RVFV have played a crucial role in understanding virus replication, virus cell interac-
tions, and the development of several virus-like particle (VLP) systems or rationally
attenuated live-virus vaccine candidates (33–42). Live-attenuated RVFV vaccine candi-
dates currently in trials were designed by deleting virulence factors (such as NSs and
NSm) or by utilizing RVFV with naturally occurring deletions in virulence genes (43–46).
To this end, we sought in this study to generate recombinant SFTS phleboviruses
that contain truncations in the NSs open reading frame (ORF) or have the NSs ORF
Brennan et al. Journal of Virology
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replaced by a foreign gene of interest. Initial attempts made to recover recombinant
SFTS phleboviruses lacking the NSs ORF failed to yield infectious virus despite repeated
rescue experiments, including those where NSs was supplied in trans or where rescue
experiments were performed in cells stably expressing SFTSV NSs. These data led us to
believe that the SFTSV NSs protein or a sequence encoded within the NSs ORF was
necessary for the recovery of infectious virus. Next, we generated a recombinant virus
(rHB29NSsKO) in which the ﬁrst two methionine residues were mutated to alanine and
several stop codons were introduced in the coding sequence of NSs to abrogate
protein expression. We demonstrate that in rHB29NSsKO-infected cells, NSs was not
expressed and the virus could no longer form plaques in infected cell monolayers. In
addition, rHB29NSsKO was unable to antagonize the production of IFN produced in
response to infection and displayed faster replication kinetics in cells with a defective
IFN response. Importantly, we demonstrate for the ﬁrst time in the context of a virus
infection that SFTSV NSs was responsible for the block in IFN production seen in
SFTSV-infected cells. As it was evident that NSs protein was not essential for SFTSV
replication but that some sequence within the NSs ORF was necessary for virus
recovery, we mapped the 3= ends of the N and NSs mRNAs produced in infected cells
by 3= rapid ampliﬁcation of cDNA ends (RACE). We found that the N and NSs mRNAs
overlapped, as previously noted for other phleboviruses, and that the 3= end of the
mRNAs extended past the IGR to terminate within the coding region of the gene
encoded in the opposite orientation. We determined that the N mRNA terminates just
downstream of a 5=-GCCAGCC-3= nucleotide motif residing in the NSs ORF encoding
amino acids (aa) 283 to 284 of the 292-amino-acid NSs protein. We establish that the
presence and position of this motif are crucial for recombinant virus rescue, which can
be presumably explained, as deletion of this sequence disrupts the correct termination
of the N mRNA. With this knowledge, we generated viruses with internal deletions of
NSs, viruses expressing only a 12-aa NSs peptide, and viruses that express enhanced
green ﬂuorescent protein (eGFP) or eGFP C-terminally fused to NSs from the NSs locus.
The ability of the recombinant viruses to antagonize IFN production in response to
infection was measured, and like rHB29NSsKO, viruses that did not express NSs could
not block IFN production. We also conﬁrmed that in all recombinant virus-infected cells,
the 3= end of the N mRNA terminated at the 5=-GCCAGCC-3= motif, as shown for
wild-type SFTSV. Finally, we demonstrated that the addition of the N mRNA termination
motif to an S-segment-based minigenome/virus-like particle assay increased minige-
nome activity in the presence of the viral glycoproteins in donor cells and resulted in
higher Renilla activity in recipient cells infected with virus-like particles.
The recombinant viruses generated and characterized in this study can now be
assessed as potential vaccine candidates, while also providing new tools to study the
biology of SFTS phlebovirus infection in mammals and arthropods both in vitro and
in vivo.
RESULTS
Rescue of a recombinant SFTSV that does not express the nonstructural
protein NSs but maintains S segment integrity. Early reports showed that in SFTSV-
infected cells, SFTSV NSs was found in virus-induced inclusion bodies (IBs), colocalized
with the nucleocapsid protein, and was associated with viral genomic RNAs (25). Due
to this observation, coupled with the failure of previous attempts to generate recom-
binant SFTSV that lacks expression of NSs (through the replacement of the NSs ORF
with an ORF comprising a reporter gene), it was believed that NSs may play an essential
role in virus replication (47). To address this issue and to take a different approach to
deleting the whole NSs ORF from within the S RNA (depicted in Fig. 1A), we aimed to
abrogate NSs protein expression by substituting the ﬁrst two in-frame methionine
residues with alanine residues (M1A and M16A) and introducing downstream stop
codons at residues K5*, D10*, and N19* within the NSs ORF product (Fig. 1B). These
mutations were inserted into the T7 transcription plasmid pTVT7-HB29S encoding the
full-length cDNA of the SFTSV S segment, generating plasmid pTVT7-HB29SNSsKO. This
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plasmid, along with transcription plasmids pTVT7-HB29ppM and pTVT7-HB29ppL and
expression plasmids pTM1-HB29N and pTM1-HB29ppL, was transfected into Huh7-
Lunet T7 cells to generate rHB29NSsKO. The wild-type recombinant virus rHB29pp
(herein known as rHB29) was rescued in parallel as a control. Titrations of rHB29NSsKO
and rHB29 rescue supernatants were set up in duplicate; one set of titrated superna-
tants was processed for Giemsa staining and the other for immunostaining using an
HB29 anti-N antibody. As previously documented, rHB29 readily formed easily distin-
guishable plaques visible by Giemsa staining (47). In contrast, rHB29NSsKO was detect-
able only in the immunofocus assay, producing foci of a size equivalent to that of the
Giemsa-stained plaques of rHB29 (Fig. 1C). Three independent rescue experiments were
performed, and the supernatants were used to infect Vero E6 cells to generate p1
stocks. Following passage, the mean titers of rescued rHB29 and rHB29NSsKO were
1.3 108 PFU/ml and 1.6 107 FFU/ml, respectively. To assess the synthesis of viral
proteins in infected cells, Vero E6 cells were infected at a multiplicity of infection (MOI)
of 1 and cell monolayers were harvested at 24 h postinfection (hpi) for Western
blotting. Samples were probed with antibodies to detect SFTSV N and NSs proteins and
alpha-tubulin as a loading control. N protein was readily detectable in both rHB29- and
rHB29NSsKO-infected cells, whereas NSs was detected only in cells infected with rHB29,
indicating that rHB29NSsKO does not express NSs during infection (Fig. 1D).
Growth properties of recombinant SFTSV. The growth properties of the recom-
binant viruses were assessed in human-derived interferon-competent (A549) and
interferon-incompetent (A549-NPro) cells to evaluate the contribution of NSs to virus
replication in the presence of the mammalian interferon response. A549 or A549-NPro
cells were infected at an MOI of 1, and supernatants and cell monolayers were
harvested at the time points indicated. An MOI of 1 was selected, since at lower MOIs,
such as 0.1 focus-forming unit (FFU)/cell, rHB29NSsKO was unable to establish infection
and replicate in A549 cells (data not shown). Viral supernatants were titrated on Vero
E6 cells by plaque- and focus-forming assays. The parental virus rHB29 replicated
efﬁciently, with similar growth kinetics in both A549 and A549-NPro cells, achieving
peak titers of 1.1 106 PFU/ml and 1.3 106 PFU/ml, respectively (Fig. 2A). However,
rHB29NSsKO replicated more efﬁciently in cells that had a defective interferon response
FIG 1 Recovery of a recombinant SFTSV that cannot express the virally encoded NSs protein. (A) Schematic depiction of the parental SFTSV S segment coding
strategy, showing transcription of the NSs ORF encoding subgenomic mRNA from the antigenomic S RNA. (B) Alignment of the genomic S RNA coding
sequences of rHB29 and rHB29NSsKO, showing the mutations made to abrogate the translation of the NSs protein from the NSs subgenomic mRNA
(underlined). (C) Comparison of plaque or focus sizes of rHB29 and rHB29NSsKO on Vero E6 cells. Cell monolayers were ﬁxed 5 days postinfection with 4%
formaldehyde and stained with Giemsa solution or immunostained with anti-HB29 N antibody for a focus-forming assay; the average titers for 3 rescues are
presented. (D) Vero E6 cells were infected at an MOI of 1 PFU or FFU/cell with recombinant viruses. At 24 hpi, lysates of infected cell monolayers were harvested
and subjected to Western blotting. Blots were probed using anti-tubulin, anti-HB29 N, and anti-HB29 NSs antibodies.
Brennan et al. Journal of Virology
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(P  0.05), reaching a peak titer 1 log higher in A549-NPro cells at 48 hpi (1.6 106
FFU/ml in A549-NPro cells compared to 1.4 105 FFU/ml in A549 cells) (Fig. 2B).
Western blotting of infected cell lysates collected throughout the time course
revealed no substantial difference in the synthesis of the N or NSs proteins in either
rHB29-infected A549 or A549-NPro cells. In both cases, accumulation of nucleocapsid
protein was detected at 20 hpi and the protein continued to accumulate throughout
the time course. NSs produced by rHB29 was also clearly detected from 20 hpi in both
cell lines (Fig. 2C). In the case of the NSs knockout virus, N protein accumulated slowly
in infected A549 cells and appeared to decrease at 48 hpi, reﬂecting the reduced
replication kinetics observed in the growth curve (Fig. 2B). However, much greater
accumulation of N protein was detected in the lysates from rHB29NSsKO-infected
A549-NPro cells when the blots were exposed for the same length of time. Expression
of NSs protein was not observed at any time point in either cell line infected with the
NSs knockout virus (Fig. 2D). These data conclusively demonstrate that SFTSV NSs is not
essential for virus replication in mammalian cells. The data also show that rHB29NSsKO
replication is enhanced in cells lacking a functional IFN response compared to parental
cells, where an IFN response is still intact.
SFTSV NSs mediates IFN antagonism during infection. We next carried out a
biological IFN assay on cell culture supernatants collected during the time course
described in Fig. 2. Brieﬂy, supernatants from recombinant virus-infected A549 cells
were collected at the time points indicated (on Fig. 2A and B) and UV inactivated. Serial
dilutions of the inactivated supernatants were then used to treat IFN-responsive
A549-NPro cells for 24 h. Cells were then infected with IFN-sensitive encephalomyo-
carditis virus (EMCV) for 4 days to allow the cytopathic effect (CPE) to develop (48–51).
Figure 3 shows that despite the fact that rHB29 encodes a potent IFN antagonist
FIG 2 Growth properties of recombinant viruses. (A and B) Viral growth curves were determined for A549
or A549-NPro cells infected at a low MOI (0.1) with rHB29 (A) or rHB29NSsKO (B), and titers were measured
by plaque assay or immunofocus assay as appropriate. Graphs show the average results of 3 experiments;
all titrations were carried out at the same time (*, P  0.05). (C and D) Western blot analysis of
S-segment-encoded proteins from rHB29 (C)- or rHB29NSsKO (D)-infected cells. Cell extracts were prepared
from the growth curve samples at the time points indicated, proteins were fractionated on 4-to-12%
NuPage gels, and blots were probed with anti-HB29 N, anti-HB29 NSs, and anti-tubulin antibodies as
indicated.
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(22–27), rHB29 infection induced the production of interferon beginning at 20 hpi,
reaching a maximum by 48 hpi. In comparison, rHB29NSsKO infection induced an IFN
response early on (12 hpi), and the response increased rapidly for the remainder of the
time course (P  0.0001). The data indicate that during parental virus infection, IFN is
induced in response to infection and that this induction can be partially controlled by
the expression of the viral NSs protein. These data also conﬁrm that in the context of
virus infection, SFTSV NSs acts as an IFN antagonist, in agreement with previous studies
on bunyavirus NSs proteins (29, 31, 45, 52–56) and SFTSV NSs (22–27).
Identiﬁcation of the 3= termini of SFTSV S-segment-derived mRNAs. The data
described in the previous paragraphs demonstrate that NSs protein expression is not
essential for SFTSV replication (Fig. 1). We next wanted to explore if there were any
essential signals/sequences at the nucleotide level within the S RNA that might be
preventing the successful recovery of a full NSs deletant virus through the deletion of
the NSs ORF. To this end, we speciﬁcally wanted to identify the 3= ends of the N and
NSs mRNAs to establish the point at which the subgenomic mRNAs terminate within
the viral RNA and pinpoint any motifs responsible for transcription termination. To
facilitate this characterization, total cellular RNA was extracted from four independent
replicates of rHB29-infected Vero E6 cells and 3= RACE analysis was performed after in
vitro polyadenylation with Escherichia coli poly(A) polymerase (E-PAP). Ampliﬁcation of
the 3= end of the mRNA was achieved through reverse transcription-PCR (RT-PCR) with
a primer speciﬁc for either the N or NSs mRNA and an oligo(dT) anchor primer. The PCR
products were then sequenced (Fig. 4). In all four independent replicates, the 3= end of
the N mRNA was located at position 24 situated with respect to the start of the IGR,
meaning that the N mRNA terminated within the antisense NSs ORF of the genomic
RNA template (Fig. 4A). It was noted that this was upstream of a 7-nt sequence motif,
5=-GCCAGCC-3=, at positions34 to28, a motif similar to that ﬁrst described for RVFV
(12). The NSs mRNA terminated at position 78 within the antisense N ORF. Unlike that
seen for the N mRNA, no 5=-GCCAGCC-3= motif was observed upstream of the NSs
mRNA termination site within the viral antigenomic RNA. However, there are several
FIG 3 Interferon is induced to high levels in rHB29NSsKO-infected cells. Cell culture supernatants from
viral growth curve samples were collected at the indicated time points. Samples from two experimental
repeats were UV inactivated, and the numbers of relative IFN units were measured by a biological IFN
assay. Error bars indicate the SD of the mean; ****, P  0.0001; **, P  0.01.
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termination motifs identical to that seen with RVFV N and NSs mRNAs (5=-GCUGC-3=)
located near the termination site at positions 71 to 75, 74 to 78, 77 to 81, and 89 to 93
(Fig. 4B) (11–13). As it was now apparent that a small portion of the 3= end of the NSs
coding sequence was utilized by the virus for N mRNA transcription termination, we
next pinpointed the exact motif responsible for mRNA termination and examined
whether this information would facilitate the successful recovery of viruses in which the
coding sequence for NSs was replaced with another gene of interest (see below).
Generation of recombinant SFTSVs with truncated or deleted NSs ORFs. To
assess the contribution of the putative N mRNA transcription termination motif
(5=-GCCAGCC-3=) to the efﬁciency of recombinant virus rescue, a series of NSs trunca-
tion mutants was generated. First, the termination motif was aligned to determine
where in the NSs amino acid sequence the motif resided (Fig. 5A). The termination
motif was predicted to reside within the coding sequence for Pro-284 and Ala-285 of
the NSs ORF. A series of NSs ORF C-terminal truncation mutations (Cdel5 to Cdel20)
from the stop codon at aa position 294 or N-terminal truncation mutations (Ndel5 to
Ndel19) from Ala-274 was generated by excision PCR of the cDNA plasmid pTVT7-
HB29S. The cDNA constructs were used in our rescue system to recover recombinant
viruses in three independent experiments and then passaged once in Vero E6 cells to
generate working stocks of virus. Figure 5C shows that only recombinant viruses
containing Ndel5 and Ndel10 were recovered at titers (2.2 and 2.5 108 PFU/ml,
respectively) similar to that of the parental rHB29 (2.4 108 PFU/ml). Experiments to
recover recombinant viruses containing NSs Ndel15 to Ndel19 deletion mutants did not
yield any infectious virus in any of the independent experiments, indicating that the
efﬁcient/correct termination of the N mRNA was crucial for virus rescue. The recovery
of the recombinant virus containing the Ndel10 mutant was surprising, as the Ndel10
mutation should have disrupted the 5=-GCCAGCC-3= transcription termination motif.
FIG 4 Mapping of the 3= ends of HB29 N and NSs mRNA. Data are shown for four independent infections, RNA extractions, and 3= RACE analyses of the N (A)
and NSs (B) mRNAs of rHB29-infected cells collected 24 hpi. The sequences of the viral genomic or antigenomic S RNA and the N or NSs mRNAs are aligned.
The intergenic region (uppercase) is shown from positions 1 to 54, and the N mRNA termination motifs 5=-GCCAGCC-3= (white box) and 5=-GGCUGGC-3= (black
box) or NSs termination motifs 5=-GCUGC-3= (white box, dashed outline) and 5=-GCAGC-3= (hatched box) are shown. The N and NSs open reading frames are
shown in lowercase. Arrows indicate the site of in vitro poly(A) addition.
Mapping SFTSV S Segment mRNA Transcription Termination Journal of Virology
August 2017 Volume 91 Issue 16 e00743-17 jvi.asm.org 7
 o
n
 August 24, 2017 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
However, on examination of the nucleotide sequence of the truncation mutant at the
truncation site, a nucleotide sequence of 5=-GCCGCC-3= was generated in the same
position as the authentic signal. Furthermore, 3= RACE analysis conﬁrmed that this
motif is being used as an alternative transcription termination signal for the N mRNA,
facilitating the recovery of the recombinant virus (Fig. S1). In contrast to the
N-terminal truncations, none of the rescue experiments that include the C-terminal
FIG 5 Generation of recombinant SFTS phleboviruses with truncated or deleted NSs ORFs. (A) Schematic depiction of putative N mRNA transcription
termination signal and corresponding position in the NSs ORF. An arrow indicates the site of in vitro poly(A) addition. (B) NSs truncation mutants were made
from either the C terminus of the NSs ORF product (upper panel) or N terminally from aa 274 to the stop codon in pTVT7-HB29S (lower panel). (C) The modiﬁed
constructs illustrated in panels B and D were used in a reverse system to attempt to recover recombinant viruses. Brieﬂy, rescue supernatants from transfected
cells were collected at 5 days posttransfection and passaged onto Vero E6 cells. Monolayers were harvested at 7 days postinfection and titrated by plaque- or
focus-forming assay on Vero E6 cells. Data are presented as an average result of three independent rescue experiments. (D) Modiﬁed pTVT7-HB29S cDNA
constructs were generated expressing only a methionine and the last 11 aa of the NSs ORF product (a 96% deletion of the NSs coding sequence) or expressing
a foreign gene of interest by fusing the last 11 aa of the NSs ORF product to the C terminus of the gene, as indicated in the diagram and also used in the reverse
genetics system to recover recombinant viruses. (E) A549 cells were infected with recombinant viruses at an MOI of 1 PFU or FFU/cell. At the indicated time
points, cell culture supernatants from infected cells were collected. Samples from three experimental repeats were UV inactivated, and the relative IFN units
were measured by a biological IFN assay. Error bars indicate the SEM; ****, P  0.0001.
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truncations yielded infectious virus. This was unexpected, as the Cdel5 mutant still
contained the 5=-GCCAGCC-3= motif.
Next, we wanted to conﬁrm if the 5=-GCCAGCC-3= motif was necessary for efﬁcient
virus rescue by truncating the NSs ORF within pTVT7-HB29S to encode a 12-aa
sequence containing a methionine and the last 11 amino acid residues of the NSs ORF
product (MWPAIGDLPKEV*; underlining indicates the amino acids in which the tran-
scription termination resides) (rHB2912aaNSs). The sequence encoding this short NSs
peptide contains the 5=-GCCAGCC-3= nucleotide motif at the same number of nucle-
otides away from the N ORF stop codon (Fig. 5D). We once again used this plasmid
in our reverse genetics system and passaged it once in Vero E6 cells, on all
occasions recovering rHB2912aaNSs virus with an average titer of 4.4 107 FFU/ml,
almost 10-fold less than that of the wild-type virus (Fig. 5C). The successful rescue
of rHB2912aaNSs indicated that the 36-nt sequence containing the 5=-GCCAGCC-3=
motif seemed to be necessary for virus rescue. Therefore, we generated a further set
of recombinant S segment transcription plasmids in which the coding sequences of
enhanced green ﬂuorescent protein (eGFP) or NSseGFP (eGFP C-terminally fused to
the HB29 NSs ORF) were cloned into the truncated NSs locus retaining the essential
short peptide sequence described earlier (Fig. 5D). Recovery of the rHB29delNSsGFP
and rHB29NSsGFP-FUSE recombinant viruses (with average stock titers of 3.0 107
PFU/ml and 8.2 105 PFU/ml, respectively) was achieved. Successful rescue of these
viruses demonstrated conclusively that the NSs protein is not necessary for viral
replication in infected cell monolayers and that the NSs ORF (apart from the sequence
encoding aa 283 to 294) can be replaced with foreign genes of interest.
As NSs has been demonstrated to antagonize the mammalian IFN response, we
wanted to see if our new recombinant viruses were able to prevent the production
of IFN during infection. Brieﬂy, A549 cells were infected with recombinant viruses
at an MOI of 1 PFU/cell (rHB29, rHB29NSsNdel10, rHB2912aaNSs, rHB29delNSsGFP,
rHB29NSsGFP-FUSE, or rHB29NSsKO), and infected cell supernatants were harvested at
the time points indicated, UV inactivated, and subjected to a biological IFN assay as
described in the previous paragraph. The data show that recombinant viruses contain-
ing intact or nearly complete NSs ORFs (rHB29NSsNdel10 or rHB29NSsGFP-FUSE) could
antagonize IFN production as efﬁciently as the parental virus rHB29 at all time points
tested. Conversely, recombinant viruses in which NSs expression was abrogated
(rHB2912aaNSs, rHB29delNSsGFP, or rHB29NSsKO) induced large amounts of IFN from
as early as 12 hpi, resulting in the production of signiﬁcantly more IFN (P 0.0001) than
that of the parental virus by 48 hpi (Fig. 5E).
As we generated recombinant viruses that expressed eGFP or NSs tagged with eGFP
that can form IBs, we wanted to examine the expression of the reporter genes in
infected cells. Vero E6 cells were mock infected or infected with rHB29delNSsGFP or
rHB29NSsGFP-FUSE at an MOI of 3 PFU or FFU/cell. At 24 hpi, cell monolayers were
observed for eGFP autoﬂuorescence on an EVOS FL microscope (Fig. 6A to C). As shown
in Fig. 6, eGFP signal was seen diffusely spread through the monolayer of cells infected
with rHB29delNSsGFP (Fig. 6B), compared to the mock-infected cells (Fig. 6A). The eGFP
signal in rHB29NSsGFP-FUSE-infected cells showed the distinct punctate cytoplasmic
staining associated with SFTSV NSs IBs described by many in infected cells (Fig. 6C) (22,
24, 47). The formation of the eGFP fusion inclusion bodies was further investigated by
staining for NSs with anti-NSs serum and by visualizing 4=,6-diamidino-2-phenylindole
(DAPI) (Fig. 6D), NSs (Fig. 6E), and eGFP (Fig. 6F) signal by confocal microscopy. As seen
in Fig. 6G, the eGFP signal strongly colocalized with the NSs signal, indicating that the
eGFP tag did not interfere with the formation of the NSs inclusion bodies present in
infected cells.
SFTSV N mRNA transcription termination occurs at the 5=-GCCAGCC-3= tran-
scription termination motif in S RNA of recombinant viruses. 3= RACE analysis of
infected cell RNA was used to conﬁrm the utilization of the 5=-GCCAGCC-3= motif as the
signal for N mRNA termination within recombinant virus S RNA. Brieﬂy, Vero E6 cells
were infected with recombinant viruses at an MOI of 1 PFU or FFU/cell. Twenty-four hpi,
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total cellular RNA was extracted from infected cell monolayers, reverse transcribed
using an oligo(dT) anchor primer, and subjected to 3= RACE analysis as described above.
Identical to the ﬁndings previously described in Fig. 4, the 3= end of the rHB29 N mRNA
was found to terminate upstream of the 7-nt 5=-GCCAGCC-3= sequence motif at
positions 34 to 28 (Fig. 7). Moreover, 3= RACE data from RNA derived from cells
infected with rHB2912aaNSs (expressing only the last 11 aa residues of the NSs ORF
product from the NSs locus within the S RNA) showed that the 3= end of the N mRNA
was located at position 23 or 24, terminating in the same position as the parental
virus rHB29. All other recombinant viruses containing the 36-nt sequence containing
FIG 6 (A to C) Visualization of recombinant virus-infected cells. eGFP autoﬂuorescence in Vero E6 cells mock infected (A) or infected with rHB29delNSsGFP (B)
or rHB29NSsGFP-FUSE (C) imaged at 24 hpi. The boxes highlight differences in eGFP expression in infected cell monolayers. Bar, 1,000 m. (D to G) To assess
whether the eGFP signal detected in rHB29NSsGFP-FUSE-infected cells colocalized with NSs expression, Vero E6 cells were infected with rHB29NSsGFP-FUSE
at an MOI of 1, and the cell monolayer was ﬁxed in 4% formaldehyde at 24 hpi, followed by costaining with anti-HB29 NSs (red) or DAPI (blue) and examination
for eGFP autoﬂuorescence by confocal microscopy. Bar, 10 m.
FIG 7 3= RACE analysis conﬁrms that the 3= end of the N mRNA terminates at the same position in all recombinant viruses. Vero E6 cells were infected with
recombinant virus rHB29, rHB1912aaNSs, rHB29delNSsGFP, rHB29NSsGFP-FUSE, or rHB29NSsKO at an MOI of 1 PFU or FFU/cell. At 24 hpi, cell monolayers were
harvested; total cell RNA was extracted, and 3= RACE analysis was performed. The sequences of the viral genomic S RNA and the N mRNA derived from
recombinant virus-infected cells are aligned. The intergenic region (uppercase) is shown from positions 1 to 54, and the N mRNA termination motif
5=-GCCAGCC-3= (white box) is shown. The N and NSs open reading frames are shown in lowercase. Arrows indicate the site of in vitro poly(A) addition.
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the 5=-GCCAGCC-3= motif and encoding the terminal 11 aa of the NSs ORF product
(rHB29delNSsGFP, rHB29NSsGFP-FUSE, or rHB29NSsKO) had N mRNA terminating at
identical positions in the S RNA, upstream of the putative termination motif at positions
34 to 28. These data, especially the 3= RACE data obtained for rHB2912aaNSs,
strongly suggest that the 5=-GCCAGCC-3= motif is the transcriptional termination signal
for the N subgenomic mRNA (Fig. 7).
S segment-based minigenome and VLP assays containing the N mRNA tran-
scription termination motif show increased activity. Finally, we sought to decipher
how the addition of the N mRNA termination signal affected the replication of viral
ribonucleoproteins (RNPs) as well as the production of progeny virus particles, using an
S-segment-based minigenome and virus-like particle assays. The minigenome system
has been described previously (47). Brieﬂy, Huh7-Lunet T7 cells which express T7 RNA
polymerase were transfected with plasmids pTM1-N and pTM1-L and either pTVT7-
HB29SdelNSs:hRen (T7-hRen) or pTVT7-HB29SdelNSs:hRenCT (T7-hRenCT; containing
the 36-nt NSs coding sequence). To generate virus-like particles from transfected cells,
plasmid pTM1-HB29GnGc expressing the SFTSV viral glycoproteins (Gn and Gc) was
also included in the transfection mix where indicated on Fig. 8. At 48 h posttransfection,
cell monolayers were harvested to measure ﬁreﬂy luciferase (FFLuc) and humanized
Renilla luciferase (hRen) activity, and cell culture supernatants from donor cells (mini-
genomes with or without viral glycoproteins) were harvested and nuclease treated to
eliminate any cDNA plasmid carryover (Fig. 8A). Both minigenomes showed increased
activity over the negative control (L, GnGc) by 48 h posttransfection. However,
inclusion of T7-hRenCT in the minigenome system led to a higher Renilla luciferase
signal than when T7-hRen was used. The addition of the viral glycoproteins to the
system (to generate VLPs) led to a statistically signiﬁcant increase (P  0.05) in
minigenome activity in the T7-hRenCT-based minigenome compared to that of the
minigenome containing just the hRen ORF. This difference is presumably mediated by
the efﬁcient production of virus particles in the T7-hRenCT system that can reinfect cells
once produced, to boost Renilla luciferase signal. As this boost was not seen for
FIG 8 S-segment-based minigenome and VLP assays containing the N mRNA transcription termination motif show increased activity. (A)
Effect of the addition of an 11-aa portion of the SFTSV NSs ORF product to the C-terminal end of the hRen gene on an S-segment-based
minigenome with or without the inclusion of the viral glycoproteins in donor cells. Huh7-Lunet T7 cells were transfected with pTMFFluc
(to measure ﬁreﬂy luciferase activity as an internal control of transfection efﬁciency and data normalization), pTVT7-HB29SdelNSs:hRen
(T7-hRen), or pTVT7-HB29SdelNSs:hRenCT (T7-hRenCT) and pTM1-N, pTM1-L, or pTM1-GnGc where indicated. Empty pTM1 vector was
used to ensure that the total amount of DNA used in each transfection was the same. Cell culture supernatants were harvested and
nuclease treated, and ﬁreﬂy and Renilla luciferase activities were measured in transfected cell monolayers at 48 h posttransfection (h p.t.).
(B) Luciferase activity in recipient cells. Nuclease-treated cell culture supernatants from the donor cells were adsorbed onto recipient
Huh7-Lunet T7 cells for 1 h. Fireﬂy luciferase and humanized Renilla luciferase were measured in VLP-infected recipient cells at 18 hpi.
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T7-hRen-transfected cells, it is possible that although minigenome activity was de-
tected, it was not enough to amplify the Renilla signal, a crucial step for the recovery
of recombinant viruses in reverse genetic systems.
Renilla and ﬁreﬂy luciferase signals were measured in VLP-infected cells at 18 hpi.
Only the supernatant of cells that had been cotransfected with pTVT7-HB29GnGc
produced Renilla activity in recipient cells (Fig. 8B; L, GnGc), demonstrating that
minigenomes were efﬁciently packaged into VLPs capable of infecting naive cells. The
results also demonstrate that the nuclease digestion was sufﬁcient to prevent plasmid
transfer from donor to recipient cells (Fig. 8B;L,GnGc). Huh7-Lunet T7 cells infected
with VLPs containing the T7-hRenCT minigenome had twice the activity of those
containing T7-hRen (P  0.05). These data indicate that the presence of the N mRNA
transcription termination signal in T7-hRenCT leads to the efﬁcient synthesis of N mRNA
in T7-hRenCT-transfected cells, which results in increased minigenome activity in the
donor cells. In the presence of the viral glycoproteins, this activity was ampliﬁed and
could be efﬁciently transferred to recipient cells.
DISCUSSION
The nonstructural (NSs) proteins of bunyaviruses are well documented as the main
virulence determinant of infection and the primary virally encoded innate immune
antagonist (27–32, 43–45, 50–52, 54, 55, 57–65). For this reason, research has been
conducted to create and utilize NSs deletant viruses or viruses that contain natural
truncations of the NSs proteins as potential live-attenuated vaccine candidates (34, 43,
44, 46, 55, 66, 67). In 2009, a novel tick-borne Phlebovirus, SFTSV, emerged in China. The
virus caused severe disease in humans and had a high case fatality rate of 12 to 15%
(15, 16). Upon the discovery of the virus, work began to investigate the contribution of
SFTSV NSs to innate immune evasion and the pathogenesis of disease (22–27). The
successful recovery of SFTSV entirely from cDNA clones was published in 2015 (47), with
the aim of generating viruses lacking NSs proteins to facilitate pathogenesis studies and
to develop novel vaccine candidates.
However, initial attempts to recover recombinant viruses in which the NSs ORF had
been replaced with that of any foreign gene of interest before the publication of the
reverse genetics system failed. Methodologies included direct rescues of NSs deletant
viruses, trans-complementation of NSs in rescue experiments, and generation of NSs-
expressing cell lines in which the rescue system could be used (data not shown). Work
by Wu et al. (25) described a potential role for NSs in viral replication due to interactions
of NSs with viral RNA and the nucleocapsid protein within the viroplasm-like structures
present in infected cells. These data suggested that the recovery of recombinant viruses
lacking NSs might not be possible due to an essential role of NSs in the viral replication
cycle. However, data from minigenome experiments in which the NSs ORF had been
replaced with the humanized Renilla luciferase gene indicated that RNP formation,
replication of the RNPs, and subsequent Renilla luciferase expression was possible in
the absence of NSs. In fact, the data showed that NSs inhibited minigenome activity
when overexpressed in the system (47). With these data in mind, we hypothesized that
the NSs protein itself may not be necessary for the formation of viral RNPs and hence
virus replication. Here we show instead that the success of a given recombinant virus
rescue could be determined by a signal or structure residing within the NSs nucleotide
sequence.
We report the successful generation of recombinant NSs deletion mutant viruses
through the mapping of the 3= end of the N mRNA synthesized from the viral
genomic RNA during infection. Surprisingly, even without synthesizing NSs (the
well-documented interferon antagonist for SFTSV [22–27]), rHB29NSsKO could still
replicate in A549 cells, albeit to lower levels (Fig. 2), perhaps suggesting that another
virally encoded protein could have IFN antagonistic functions, an avenue of research
worth exploring with future experimentation. To our knowledge, the data presented
here are the ﬁrst report that SFTSV NSs is responsible for biological IFN antagonism in
the context of a virus infection (Fig. 3 and 5). This result highlights the importance of
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demonstrating the IFN antagonist activity of SFTSV NSs in the context of a virus
infection. It was hypothesized that the reason for the enhanced pathogenicity of SFTSV
was due to the antagonistic effect of NSs on the innate immune response. However,
despite the fact that SFTSV encodes such a potent IFN antagonist, the synthesis of NSs
in infected cells was not sufﬁcient to efﬁciently block IFN production as a result of virus
infection. Recent work has also shown that the severity of SFTS disease in SFTSV-
infected patients correlates with high levels of IFN alpha (IFN-), tumor necrosis factor
alpha (TNF-), granulocyte colony-stimulating factor (G-CSF), IFN-, macrophage in-
ﬂammatory protein 1 (MIP-1), interleukin 6 (IL-6), IL-10, interferon-inducible protein
10 (IP-10), and monocyte chemoattractant protein 1 (MCP-1), suggesting that in an in
vivo setting, the ability of SFTSV NSs to antagonize the IFN response may be limited to
type-I interferon induction and signaling (68).
From the data presented, it was clear that the NSs protein was not necessary for
virus rescue or virus replication, even in cells with a functional IFN response. Our data
also suggested that some part of the nucleotide sequence encoding NSs could be
crucial for the recovery of recombinant viruses. Viruses within the Phlebovirus genus
utilize an ambisense coding strategy to generate subgenomic mRNA transcripts ex-
pressing the N and NSs ORFs in opposite orientations, separated by an intergenic
region (IGR) (3). Previous studies on several viruses, including RVFV (11–13), UUKV
(6), and TOSV (14), have characterized and mapped the location of the 3= end of the
S-segment-derived mRNAs. For RVFV, both the N and NSs mRNAs were found to
terminate within the IGR, downstream of a 5=-GCUGC-3= motif (11–13). For UUKV, the
N mRNA terminates in the IGR just before the end of the NSs ORF expressed in the
opposite orientation, whereas the 3= end of the NSs mRNA was mapped to a position
within the N ORF expressed in the opposite orientation (6). Finally, the reverse situation
was found to be true for TOSV, where the 3= end of the NSs mRNA terminated just
before the end of the N ORF and the N mRNA terminated at a position within the NSs
ORF expressed in the opposite orientation, as summarized in Fig. 9. For SFTSV, we
found that the 3= end of both the N and NSs mRNAs mapped to positions within the
coding sequence of the opposite gene (Fig. 4). Further mutational analysis determined
that the termination of the N mRNA transcript was just prior to an upstream 5=-GCCA
GCC-3= motif, residing in the sequence encoding amino acids P-284 and A-285 of the
NSs ORF product. We also conﬁrmed that the nucleotide sequence 5=-GCCGCC-3= in the
FIG 9 S-segment-derived mRNA termination of selected phleboviruses. A schematic representation is
shown indicating where the 3= ends of the N and NSs mRNAs of select phleboviruses map on the S RNA
segment (not to scale). The size of each respective IGR is given. The 5= cap structure on mRNA is depicted
by a black circle. Black and white squares represent the N and NSs transcriptional termination signals,
respectively. IGR, intergenic region; RVFV, Rift Valley fever phlebovirus; TOSV, Toscana virus; UUKV,
Uukuniemi phlebovirus; SFTSV, SFTS phlebovirus.
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same position as the authentic motif can be utilized as an alternative transcription
termination signal in recombinant virus rHB29NSsNdel10.
For the C-terminal set of truncation mutants, no infectious virus was recovered in
our reverse genetics system, even when amino acids P-284 and A-285 were present
(Fig. 5B and D). However, in this case, the C-terminal truncation mutants resulted in the
shortening of the distance between the N ORF stop codon and the transcription
termination signal with each subsequent truncation. Work by Barr in 2004 on Buny-
amwera orthobunyavirus (69) and by Lara et al. in 2011 on RVFV (13) proposed that
there is a minimum distance between the N ORF stop codon and the transcription
termination motif required for the RdRp to recognize the termination motif and detach,
resulting in efﬁcient N mRNA synthesis. Therefore, it is possible that the Cdel5 trunca-
tion moved the termination signal within this minimum distance, preventing the
termination motif from being utilized by the transcribing RdRp, a hypothesis that will
be explored in future studies.
Importantly, all recombinant viruses that encoded a full or partially truncated NSs
(rHB29, rHB29NSsNdel10, and rHB29NSsGFP-FUSE) antagonize the production of IFN
induced by virus infection as efﬁciently as the parental virus. Conversely, viruses that
could not express NSs in infected cells (rHB2912aaNSs, rHB29delNSseGFP, and
rHB29NSsKO) induced large amounts of IFN at late time points. rHB29NSsKO replication
in A549 cells induced considerably more IFN production than the other NSs deletant
viruses (Fig. 5E). This could be due to the production of an NSs mRNA that hybridizes
with the S segment RNA to form double-stranded RNA (dsRNA), which could be sensed
by melanoma differentiation-associated gene 5 (MDA-5) (70), an area to be elucidated
further with time.
Finally, we wanted to assess how the presence of the 5=-GCCAGCC-3= motif con-
tributed to the ability to rescue recombinant NSs deletant viruses. This was assessed in
the context of a virus-like particle formation assay to give a quantitative measure of
RNP replication and packaging into virus particles. This process would be crucial for the
efﬁcient recovery of any attenuated or mutant recombinant viruses in a rescue system.
In Fig. 8, we hypothesize that in both systems tested, the minigenome RNPs are formed
and packaged into VLPs along with transiently expressed or encapsidated N protein
from the donor cells, allowing for RNP replication and transcription and hence the
detection of Renilla luciferase in the VLP-infected recipient cells. However, in
T7-hRenCT-VLP-infected recipient cells, the minigenome RNPs would be able to
efﬁciently synthesize additional N mRNA, which when translated into N protein will
help increase the Renilla luciferase signal. This boost in signal, mediated by further
N protein expression, translated from nascent N mRNA transcription in recipient cells,
would be ampliﬁed over multiple rounds of replication and therefore be crucial in the
ability to recover recombinant viruses in a rescue system.
In conclusion, we have demonstrated that SFTSV NSs protein is not essential for
virus replication in vitro. Using an NSs knockout virus, we show that SFTSV NSs is
responsible for antagonism of the innate immune response in the context of a virus
infection. We have utilized 3= RACE to map the 3= end of the N mRNA, which allowed
us to generate recombinant NSs deletant viruses that can be used for future studies on
virus replication in vitro and in vivo and have the potential to be used as live-attenuated
vaccine candidates to prevent spread of this important emerging pathogen.
MATERIALS AND METHODS
Cells and viruses. A549 and Vero E6 cells (commonly used cell lines originally obtained from the
European Collection of Authenticated Cell Cultures [ECACC] and previously described in references 48
and 71); Vero E6 from Institut Pasteur) were grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
supplemented with 10% fetal calf serum (FCS), and A549/BVDV-Npro (herein known as A549-NPro) cells
(48) were grown in the same medium supplemented with 2 g/ml puromycin (Melford Laboratories Ltd.).
Huh7-Lunet T7 cells (72), which stably express T7 RNA polymerase, were obtained from R. Bartenschlager
and were grown in DMEM supplemented with 2 mM L-glutamine, nonessential amino acids, and 10%
FCS. All cell lines were grown at 37°C with 5% CO2 unless otherwise stated.
The SFTSV strain used in this study was a plaque-puriﬁed cell culture-adapted stock called Hubei
29pp (HB29pp) provided by Amy Lambert (CDC Arbovirus Diseases Branch, Division of Vector-Borne
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Infectious Diseases, Fort Collins, CO) (47) or a recombinant derivative of the virus generated by reverse
genetics (rHB29). Working stocks of SFTSV were generated in Vero E6 cells by infecting the cells at a low
multiplicity of infection (MOI) and harvesting the cell culture medium 7 days postinfection. Vero E6 cells
were chosen to grow virus stocks due to the reported lack of a type-I IFN response. All experiments with
SFTSV were conducted under containment level 3 (CL-3) conditions, approved by the UK Health and
Safety Executive.
Plasmids. Plasmids for the recovery of SFTSV have been described previously (47). pTM1-HB29ppL
and pTM1-HB29N contain the SFTSV HB29 L and N ORFs under the control of T7 promoter and
encephalomyocarditis virus (EMCV) internal ribosome entry site sequence; pTVT7-HB29S, pTVT7-HB29M,
and pTVT7-HB29ppL contain full-length cDNAs to the SFTSV strain HB29 antigenome segments ﬂanked
by T7 promoter and hepatitis delta ribozyme sequences.
Plasmid pTVT7-HB29SNSsKO (used to abrogate NSs protein expression while leaving the cDNA
sequence intact) contains full-length cDNA to the HB29 S segment in which the cDNA sequence
encoding the NSs ORF product has been modiﬁed to code for methionine-to-alanine substitutions at
amino acid positions 1 and 16 and to insert stop codons at amino acid positions 5, 10, and 19.
pTVT7-HB29S12aaNSs contains an internal deletion in the coding region of NSs (Δ2-282), leaving the
methionine and last 11 aa of the NSs ORF product intact.
A series of individual S segment plasmids was generated based on pTVT7-HB29S in which the
sequence encoding the NSs ORF product was C terminally truncated from the stop codon or N terminally
truncated from amino acid 274. pTVT7-HB29SNSsCdel5, -Cdel10, -Cdel15, and -Cdel20 encode the HB29
NSs C-terminal deletions Δ289-293, Δ284-293, Δ279-293, and Δ274-293, respectively, while pTVT7-
HB29SNSsNdel5, -Ndel10, -Ndel15, -Ndel16, -Ndel17, -Ndel18, and -Ndel19 encode the HB29 NSs
N-terminal deletions from amino acid 274, namely, Δ275-279, Δ275-284, Δ275-289, Δ275-290, Δ275-291,
Δ275-292, and Δ275-293, respectively.
pTVT7-HB29SNSseGFP-FUSE encodes an S segment that expresses NSs with eGFP fused at the C
terminus. Transcription plasmids pTVT7-HB29SdelNSs:hRen, pTVT7-HB29SdelNSs:eGFP, and pTVT7-
HB29SNSseGFP-FUSE were further modiﬁed by PCR-directed mutagenesis to add the last 11 amino acids
of the HB29 NSs coding sequence (amino acids WPAIGDLPKEV) at the C terminus of the respective
ORF product, immediately before the stop codon, resulting in the generation of plasmids pTVT7-
HB29SdelNSs:hRenCT (T7-hRenCT), pTVT7-HB29SdelNSs:eGFPCT, and pTVT7-HB29SNSseGFP-FUSECT,
respectively.
pTM1-HB29GnGc contains the HB29 M segment ORF under the control of the T7 promoter and
encephalomyocarditis virus internal ribosome entry site sequence. All cDNA constructs were conﬁrmed
by Sanger sequencing. Oligonucleotides used to construct mutant segments can be found in Table S1
in the supplemental material.
Virus titration by plaque- or focus-forming assays. Virus titers were determined by focus-forming
assays or by plaque assay in Vero E6 cells. Brieﬂy, conﬂuent monolayers of Vero E6 cells were infected
with serial dilutions of virus made in phosphate-buffered saline (PBS) containing 2% FCS and incubated
for 1 h at 37°C, followed by the addition of a Glasgow’s MEM (GMEM) overlay supplemented with 2% FCS
and 0.6% Avicel (FMC Biopolymer). The cells were incubated for 6 days before ﬁxation and staining with
crystal violet to visualize SFTSV plaques or use of focus-forming assays for recombinant viruses as
described previously (47).
Indirect immunoﬂuorescence staining and live-cell imaging. Vero E6 cells were grown to sub-
conﬂuence on glass coverslips (13-mm diameter) and infected at a high MOI (3 FFU or PFU/ml) with
recombinant viruses. At 24 hpi, the cells were ﬁxed with 4% formaldehyde in PBS. Following permea-
bilization with 0.1% Triton X-100 and 50 mM glycine in PBS, proteins were detected using eGFP
autoﬂuorescence, rabbit anti-SFTSV NSs antibody (47), and secondary anti-rabbit Alexa Fluor 568
(Thermoﬁsher). The coverslips were mounted on slides using Fluoromount-G with DAPI (eBioscience).
Fluorescently labeled proteins were visualized using a Zeiss LSM-710 confocal microscope. Images of
infected cell monolayers were also visualized for eGFP ﬂuorescence using an EVOS FL cell imaging system
(AMG; Invitrogen).
Total cell RNA extraction and RT-PCR. Vero E6 cells were infected at an MOI of 1, and total cellular
RNA was extracted at 48 hpi using TRIzol reagent (Invitrogen). For reverse transcription-PCR (RT-PCR), 1
g of total cellular RNA was mixed with a segment-speciﬁc oligonucleotide (Table S1), 0.5 mM 4
deoxynucleoside triphosphate (dNTP) mix (Promega), 40 U rRNasin (Promega), and 200 U Moloney
murine leukemia virus (M-MLV) reverse transcriptase (Promega) and incubated at 42°C for 3 h. The
resulting cDNA was used in PCRs with primers as described in Table S2, and the products were visualized
by agarose gel electrophoresis. Products of the correct size were excised from the gel and puriﬁed using
a Wizard SV gel and PCR clean-up system (Promega; A9282), followed by direct nucleotide sequencing
of the PCR product.
3= RACE. 3= rapid ampliﬁcation of cDNA ends (RACE) analysis was used to obtain both the 3=- and
5=-terminal sequences using strand-speciﬁc primers. Brieﬂy, total cellular RNA was isolated from infected
cells using TRIzol reagent (as described above), polyadenylated (Ambion; AM1350) for 1 h at 37°C, and
then puriﬁed using an RNeasy minikit (Qiagen). Twelve microliters of polyadenylated RNA was then used
in a reverse transcription reaction with M-MLV reverse transcriptase (Promega) and 100 M oligo(dT)
primer for 10 min at 65°C, followed by PCR using 0.3 M 3= RACE anchor primer and 0.3 M
segment-speciﬁc primer (Table A2) with KOD hot start DNA polymerase (Merck). Ampliﬁed products were
puriﬁed on an agarose gel, and their nucleotide sequences were determined.
Western blotting. At different time points after infection, cell lysates were prepared by the addition
of 300 l lysis buffer (100 mM Tris-HCl [pH 6.8], 4% SDS, 20% glycerol, 200 mM dithiothreitol [DTT], 0.2%
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bromophenol blue, and 25 U/ml Benzonase [Novagen]), and proteins were separated on an SDS 4-to-12%
gradient polyacrylamide gel (Invitrogen). Proteins were transferred to a Hybond-C Extra membrane
(Amersham), and the membrane was blocked by incubation in saturation buffer (PBS containing 5% dry
milk and 0.1% Tween 20) for 1 h. The membrane was reacted with anti-N or anti-NSs polyclonal rabbit
antibodies (47) or an anti-tubulin monoclonal antibody (Sigma). This was followed by incubation with
either horseradish peroxidase (HRP)-labeled anti-rabbit (Cell Signaling Technology) or anti-mouse
(Sigma) antibodies. Visualization of detected proteins was achieved using Clarity ECL blotting substrate
(Bio-Rad) and and a Bio-Rad ChemiDoc imager.
Biological assay for interferon production. A549 cells in 35-mm dishes were infected with 1 PFU
or FFU/cell of the recombinant viruses and incubated at 37°C for the times indicated on Fig. 2A and B
and 3. The medium was removed and treated with UV light to inactivate any virus (71), and 2-fold serial
dilutions of the medium were applied to A549-NPro cells for 24 h. The cells were then infected with
interferon-sensitive EMCV (0.05 PFU/cell), and the cells were incubated for 4 days at 37°C. The cells were
then ﬁxed with 4% formaldehyde and stained with Giemsa stain to monitor the development of CPE. The
relative IFN units (RIU) are expressed as 2N, where N is the number of 2-fold dilutions that protect the
reporter cells.
SFTSV VLP assays. The ability of S segment-based minigenomes to be packaged into virus-like
particles (VLPs) was carried out using VLP assays, as previously described for several bunyaviruses (39, 73,
74). Brieﬂy, subconﬂuent Huh7-Lunet T7 cells were transfected with 250 ng of the S segment-based
minigenome-encoding plasmids (pTVT7-HB29SdelNSs:hRen or pTVT7-HB29SdelNSs:hRenCT), 125 ng
pTM1-N, 25 ng pTM1-L, 250 ng pTM1-GnGc, and 25 ng pTM1-FFLuc as a transfection control. At 48 h
posttransfection, the cell culture medium was clariﬁed by centrifugation at 10,000  g for 10 min and
treated with 0.25 U/l BaseMuncher (Expedeon) for 3 h at 37°C. Huh7-Lunet T7 cells were inoculated with
the VLP-containing cell culture medium. At 18 hpi, the infected cell lysates were used to measure Renilla
and ﬁreﬂy luciferase activities using the Dual-Luciferase reporter assay system (Promega).
Generation of recombinant viruses from cDNA. Recombinant SFTSVs were generated by trans-
fecting 5  105 Huh7-Lunet T7 cells with 0.1 g pTM1-HB29ppL, 0.5 g pTM1-HB29N, and 1 g of each
pTVT7-based plasmid expressing the wild-type or recombinant viral antigenomic segments, using 3 l
TransIT-LT1 (Mirus Bio LLC) per g of DNA as the transfection reagent. After 5 days, the virus-containing
supernatants were collected, clariﬁed by low-speed centrifugation, and stored at 80°C. Stocks of
recombinant viruses were grown in Vero E6 cells at 37°C by infecting them at an MOI of 0.01 and
harvesting the culture medium at 7 days postinfection. The genome segments of the recovered viruses
were ampliﬁed by RT-PCR, and their nucleotide sequences were determined to conﬁrm that no
mutations had occurred.
Statistical analysis. All data were analyzed using Prism 7 software (GraphPad) and are presented as
the mean  standard deviation (SD) or standard error of the mean (SEM). Statistical signiﬁcance for the
comparison of means between groups was determined by the Student t test. P values of 0.05 were
considered signiﬁcant (****, P  0.0001; ***, P  0.001; **, P  0.01; *, P  0.05).
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